On the stock market since 2024, it operates in the world of health and science. It has 130 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 15% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 1,644% a year on average.
Sales run at $46.0M a year. A small number, but proof the product has real buyers.
There is $391.1M in the vault; even if every debt were paid off, $367.5M would remain.
A loss of $48.9M against $46.0M in annual sales.
This stock swings about 2.3 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, SEPN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SEPN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (57/100) says the stock isn’t cheap.